Nils Kroeger

Nils Kroeger

Auto-generated profile, based on publicly available information

Nils Kroeger

Department of Urology, University Medicine Greifswald, Greifswald, Germany

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2017 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
FKFrank Kunath
Frank Kunath
SSStefanie Schmidt
Stefanie Schmidt
LKLaura-Maria Krabbe
Laura-Maria Krabbe
AMArkadiusz Miernik
Arkadiusz Miernik
PDPhilipp Dahm
Philipp Dahm
NKNils Kroeger
Nils Kroeger

9 September 2019 in Philosophical Transactions of the Royal Society B: Biological Sciences
Verified
Journal Article
Open access
MLMartina Lachnit
Martina Lachnit
MBMatthias T. Buhmann
Matthias T. Buhmann
JKJennifer Klemm
Jennifer Klemm
NKNils Kröger
Nils Kröger
NPNicole Poulsen
Nicole Poulsen
Throughout all kingdoms of life, a large number of adhesive biomolecules have evolved to allow organisms to adhere to surfaces underwater. Proteins play an important role in the adhesion of numerous marine invertebrates (e.g. mussels, sea stars, sea urchins) whereas much less is known about the biological adhesives from marine plants, including the diatoms. Diatoms are unicellular microalgae that together with bacteria dominate marine biofilms in sunlit habitats. In this study we present the first proteomics analyses of the diatom adhesive material isolated from the tenacious fouling species Amphora coffeaeformis . We identified 21 proteins, of which 13 are diatom-specific. Ten of these proteins share a conserved C-terminal domain, termed GDPH domain, which is widespread yet not ubiquitously present in all diatom classes. Immunofluorescence localization of a GDPH domain bearing protein (Ac629) as well as two other proteins identified in this study (Ac1442, Ac9617) demonstrated that these are components of the adhesive trails that are secreted by cells that glide on surfaces. This article is part of the theme issue ‘Transdisciplinary approaches to the study of adhesion and adhesives in biological systems’.

13 August 2017 in BJU International
Verified
Journal Article
Open access
PDF file
Jens BedkeJens Bedke
Jens Bedke
JHJohannes Heide
Johannes Heide
SRSilvia Ribback
Silvia Ribback
SRSteffen Rausch
Steffen Rausch
MMMichela de Martino
Michela de Martino
NKNils Kroeger
Nils Kroeger
Objective: To validate microvascular (MVI) and lymphovascular (LVI) invasion as prognostic factors in patients with renal cell carcinoma (RCC). Patients and Methods: Data of patients with RCC who underwent radical or nephron‐sparing surgery were prospectively collected from three academic centres. The occurrence of MVI and LVI was determined with standard staining protocols by experienced pathologists at the time of diagnosis. The association of MVI and LVI with clinicopathological data, metastatic spread, and cancer‐specific survival (CSS) were evaluated with Fisher's exact tests, binary logistic regression analyses, and univariable and multivariable Cox proportional hazard regression models. Results: MVI was present in 201 of 747 patients (26.9%) and was associated with advanced Tumour‐Node‐Metastasis (TNM) stages, high Fuhrman grades, and sarcomatoid features (all P < 0.001). MVI was associated with a higher rate of metastatic spread. LVI was present in 32 of 573 patients (5.5%) and was associated with advanced TNM stages, high Fuhrman grade, and sarcomatoid features (all P < 0.001). Two‐thirds of LVI‐positive patients died ( P < 0.001). Both LVI and MVI were significantly associated with CSS in all patients, clear cell RCC (ccRCC), and localised RCC in univariable analysis (all P < 0.001). On multivariable analysis, presence of MVI was identified as an independent prognostic factor (hazard ratio 2.09; P = 0.001). Moreover, MVI [odds ratio (OR) 2.7; P = 0.001] and not macrovascular invasion ( P = 0.895) was an independent predictor of sychronuous metastatic spread. LVI was the strongest factor associated with sychronous metastatic spread (OR 4.73, 95% confidence interval 1.84–12.14; P = 0.001) in all patients and in the subgroup of patients with ccRCC ( P = 0.001). Conclusions: The present study validated LVI and MVI as prognostic factors for poor outcome in RCC. These findings endorse an evaluation of both variables in the clinical routine setting to facilitate survival prognostication in follow‐up protocols and for assignment to adjuvant treatment trials.

9 September 2021 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
KDKaroline Diesing
Karoline Diesing
SRSilvia Ribback
Silvia Ribback
SWStefan Winter
Stefan Winter
MGManuela Gellert
Manuela Gellert
AOAntonia M. Oster
Antonia M. Oster
NKNils Kroeger
Nils Kroeger
Purpose: Although p53 is rarely mutated in ccRCC, its overexpression has been linked to poor prognosis. The current study sought to elucidate the unique role of p53 in ccRCC with genomic, proteomic, and functional analyses. Materials and methods: Data from the Cancer Genome Atlas (TCGA) were evaluated for genomic and proteomic characteristics of p53; a tissue micro array (TMA) study was carried out to evaluate the association of p53 and phosphorylated p53 (pp53) with clinical outcome. Mechanistic in vitro experiments were performed to confirm a pro-apoptotic loss of p53 in ccRCC and p53 isoforms as well as posttranslational modifications of p53 where assessed to provide possible reasons for a functional inhibition of p53 in ccRCC. Results: A low somatic mutation rate of p53 could be confirmed. Although mRNA levels were correlated with poor prognosis and clinicopathological features, there was no monotonous association of mRNA levels with survival outcome. Higher p53 protein levels could be confirmed as poor prognostic features. In vitro, irradiation of ccRCC cell lines markedly induced levels of p53 and of activated (phosphorylated) p53. However, irradiated ccRCC cells demonstrated similar proliferation, migration, and p53 transcriptional activity like non-irradiated controls indicating a functional inhibition of p53. p53 isoforms and could not be correlated with clinical outcome of ccRCC patients. Conclusions: p53 is rarely mutated but the wildtype p53 is functionally inhibited in ccRCC. To investigate mechanisms that underlie functional inhibition of p53 may provide attractive therapeutic targets in ccRCC.

1 May 2017 in European Urology
Verified
Journal Article
Closed access
NKNils Kroeger
Nils Kroeger
ASArnulf Stenzl
Arnulf Stenzl
MBMartin Burchardt
Martin Burchardt
Jens BedkeJens Bedke
Jens Bedke

26 February 2016
Verified
Reference Entry
Closed access
PDF file
LKLaura-Maria Krabbe
Laura-Maria Krabbe
FKFrank Kunath
Frank Kunath
SSStefanie Schmidt
Stefanie Schmidt
AMArkadiusz Miernik
Arkadiusz Miernik
ACAnne Cleves
Anne Cleves
NKNils Kroeger
Nils Kroeger